All In Biotech

Drug Trial Radar · NCT01349049

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory FLT3-ITD Positive Acute Myeloid Leukemia (AML)

Last checked: Nov 20, 2026Latest source record: Mar 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

90

Actual

Start

Nov 21, 2011

Primary completion

Jan 20, 2015

Study completion Jan 9, 2018

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Plexxikon
First posted
May 6, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety of study drug PLX3397 at 3 dose levels (800 mg/day, 1000 mg/day, and 1200 mg/day) and explore the efficacy in patients with relapsed or refractory acute myeloid leukemia (AML). Additional dose levels beyond 1200 mg/day may be considered based on safety and efficacy observations.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • PLX3397Drug

    Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.

  • PLX3397Drug

    The drug product is available in capsule form, to be taken orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summary of Best Modified Criteria Response Results, Bridged-to-Transplant (BTT) Participants, and Composite Remission Rates in Patients on Treatment With PLX3397 (Dose Expansion, Part 2).Time frame: 1 year post dose
  2. Summary of Time-to-Event Endpoints in Patients on Treatment With PLX3397 (Dose Expansion, Part 2)Time frame: 1 year post dose

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • UCSF Helen Diller Family Family Comprehensive Cancer Center

    San Francisco, California

  • Northwestern University

    Chicago, Illinois

  • Johns Hopkins University

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • New York Presby Hospital, Weill Medical College at Cornell University

    New York, New York

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.